941
Participants
Start Date
April 17, 2020
Primary Completion Date
March 29, 2021
Study Completion Date
December 12, 2022
Convalescent Plasma
SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
Saline solution
Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
NYU Langone Health, New York
Montefiore Medical Center, The Bronx
University of Miami Hospital and Clinics, Miami
Aurora St. Luke's Medical Center, Milwaukee
Medical College of Wisconsin / Froedtert Memorial Lutheran Hospital, Milwaukee
The University of Texas Health Science Center, Tyler
The University of Texas Health Science Center, Houston
University of Texas Rio Grande Valley, Edinburg
Yale University School of Medicine, New Haven
National Center for Advancing Translational Sciences (NCATS)
NIH
Albert Einstein College of Medicine
OTHER
Yale University
OTHER
The University of Texas Health Science Center, Houston
OTHER
The University of Texas Health Science Center at Tyler
OTHER
University of Miami
OTHER
NYU Langone Health
OTHER